Rocky Mountain Cannabis Research Center

项目总结/摘要 岩石山坎纳比斯研究中心（RM-CRC） 美国最近经历了巨大的变化，在法律的地位和公众接受的， 大麻含有不同量四氢大麻酚的Receptor和医用大麻产品 (THC)大麻二酚（CBD）现在在北美广泛使用。尽管有这些变化， 关于THC和CBD的影响的研究一直缺乏。该研究中心的核心目标是 卓越的应用程序是评估，在三个研究项目，跨越新兴，中年，老年人 成年人，CBD如何影响THC的使用和对THC的主观反应，以及这些影响是否由 内源性大麻素系统（ECS）和相关脂质。为此目的， RM-CRC利用研究战略，利用三个关键的创新。首先，这些项目将采用移动的 药理学实验室收集生物样本，并评估THC和CBD对关键 神经认知和行为结果，内源性大麻素，以及其他与ECS相互作用的脂质。第二、 在FDA IND的支持下，我们持有大麻衍生的CBD，项目将随机分配参与者， CBD或安慰剂，并将参数操纵CBD的剂量或CBD产品是否含有 THC，以确定大麻衍生的CBD产品如何影响THC的效果。最后，这些项目依赖于 在我们的大麻研究分析核心（CRAC）中新设计的检测方法来测量大麻素， 代谢物、萜烯、内源性大麻素和血液样品中的其他脂质介质。数据协调 和分析核心（DHAC）将部署单一解决方案系统来支持数据收集、跨平台协调 项目，并与更大的科学界直接和通过NIH批准的存储库共享数据。 DHAC还将协调先前收集的数据（来自7个R 01，n=1359），并进行高级机器 学习分析THC和CBD血液水平，内源性大麻素和其他脂质之间的关系 调解人和行为数据。结果将为协调P50项目数据的中心范围分析提供信息。 因此，CRAC和DHAC为RM-CRC提供了显著的附加值，使中心能够 关于ECS和相关脂质的变化如何介导 THC和CBD对整个生命周期的影响。RM-CRC预计将成为外地的重要资源 通过向其他科学家提供有关CBD对精神和健康影响的数据， 结果，大麻素，代谢物和萜烯血液水平，以及100+内源性大麻素和相关脂质 约2000名参与者。

PROJECT SUMMARY/ABSTRACT ROCKY MOUNTAIN CANNABIS RESEARCH CENTER (RM-CRC) The United States has recently experienced enormous changes in the legal status and public acceptance of cannabis. Recreational and medical cannabis products that contain varying amounts of tetrahydrocannabinol (THC) and cannabidiol (CBD) are now widely available throughout North America. Despite these changes, research on the effects of THC and CBD has been lacking. The central goals of this Research Center of Excellence application are to evaluate, in three research projects that span emerging, middle-aged, and older adults, how CBD affects the use of and subjective response to THC, and whether these effects are mediated by the endocannabinoid system (ECS) and associated lipids. To that end, the three research projects within the RM-CRC utilize research strategies that capitalize on three key innovations. First, the projects will employ mobile pharmacology laboratories to collect biological samples and assess the acute effects of THC and CBD on key neurocognitive and behavioral outcomes, endocannabinoids, and other lipids that interact with the ECS. Second, under the auspices of an FDA IND we hold for hemp-derived CBD, projects will randomly assign participants to CBD or placebo and will parametrically manipulate either the dose of CBD or whether the CBD product contains THC, to determine how hemp-derived CBD products may impact the effects of THC. Finally, the projects rely on newly designed assays within our Cannabis Research Analytics Core (CRAC) to measure cannabinoids, metabolites, terpenes, endocannabinoids, and other lipid mediators in blood samples. The Data Harmonization and Analysis Core (DHAC) will deploy a single-solution system to support data collection, harmonization across projects, and sharing of the data with the larger scientific community directly and via NIH approved repositories. The DHAC will also harmonize previously collected data (from 7 R01s, n=1359) and conduct advanced machine learning analyses of the relationships between THC and CBD blood levels, endocannabinoids and other lipid mediators, and behavioral data. The results will inform center-wide analyses of the harmonized P50 project data. Thus, the CRAC and DHAC provide the RM-CRC with significant added value that will allow the Center to generate significant new knowledge with respect to how changes in the ECS and related lipids mediate the effects of THC and CBD across the lifespan. The RM-CRC is expected to be a significant resource to the field more broadly by providing other scientists access to data regarding CBD effects on psychiatric and health outcomes, cannabinoid, metabolite, and terpene blood levels, and 100+ endocannabinoids and related lipid mediators in approximately 2000 participants.